Sep 18, 2020 / 03:45PM GMT
Bradley L. Campbell - Amicus Therapeutics, Inc. - President, COO & Director
(technical difficulty)
The development for Pompe disease, and that's slated to read out early next year. And then we have a broad gene therapy pipeline, importantly, 2 clinical-stage programs in CLN6 and CLN3 Batten disease and a number of additional programs in preclinical development. And in such a strange year, it has been this year, it's been a great year so far for Amicus, even in the face of COVID and the global pandemic. Galafold, as I mentioned, is on track from a revenue perspective. Our Pompe program, we've been able to maintain the integrity of that study and really looking forward to seeing that readout and continue to progress the other programs as well.
So for the first half of the year, we've seen strong performance in our business and across our business and look forward to continued performance in the months ahead.
Questions and Answers:
Tazeen Ahmad - BofA Merrill Lynch, Research Division - VPOkay. Great. So let's dive into some detailed
Trustpilot
